IP Library Granted Patent US 7,065,402
Granted Patent B2
US 7,065,402 · App. 10/270,206 · Granted Jun 20, 2006

Detection of post-shock therapy sinusal tachycardia in active implantable defibrillator cardiovertor medical devices

Assignee: ELA Medical S.A.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,065,402
App. No.
10/270,206
Granted
Jun 20, 2006
Kind
B2
Abstract

An active implantable medical device of the defibrillation/cardioverter type able to detect a post-therapy sinusal tachycardia. This device includes circuits and logic able to detect ventricular and atrial activity; episodes of tachycardia and deliver a therapy for defibrillation and/or cardioversion, and/or antitachycardia stimulation. The detected tachycardia are classified, and there is selective control for the delivery of therapy according to the type of detected tachycardia classified. The device conducts further analysis of tachycardia after delivery of a shock therapy and is able to determine the presence of a post-therapy sinusal tachycardia, preferably by recognition of a stable ventricular rate, a 1:1 association of ventricular and atrial rates, a ventricular heart rate that is located in a range corresponding to a slow ventricular tachycardia. The device also is able to inhibit the delivery of a therapy in the presence of determined post-therapy sinusal tachycardia.

Claims (21)

1. An active implantable medical device including means for sensing ventricular and atrial activity; means for detecting a tachycardia in the sensed activity; means for classifying said detected tachycardia, said classifying means operating in an iterative manner; means for delivering a therapy; and means for selectively controlling the therapy delivering means as a function of the classified tachycardia; wherein the classification means further comprises means for analyzing a post-therapy detected tachycardia and determining whether said post-therapy detected tachycardia corresponds to a post-therapy sinusal tachycardia, and means for inhibiting the therapy delivering means from delivering a therapy in response to the determined post-therapy tachycardia being a post-therapy sinusal tachycardia.

2. The device of claim 1 wherein the classifying means further comprises means for determining an atrial rate and a ventricular rate; means for determining a stability of the ventricular rate; means for determining an association of the atrial and ventricular rates; means for determining whether the ventricular rate is in a predetermined range corresponding to a slow ventricular tachycardia range; and wherein said analyzing means determines a post-therapy sinusal tachycardia as a detected tachycardia having a stable ventricular rate, a 1:1 association of atrial and ventricular rates, and a ventricular rate in said predetermined range.

3. The device of claim 2 , further comprising means for comparing the ventricular rate to a predetermined frequency limit, wherein the analyzing means further comprises means for determining that the post-therapy detected tachycardia is a post-therapy sinusal tachycardia in response to the ventricular rate being lower than said predetermined frequency limit.

4. The device of claim 3 , further comprising means for adjusting the predetermined frequency limit to a limit between 120 and 160 bpm.

5. The device of claim 2 , wherein the classifying means further comprises means for determining a ventricular tachycardia in an absence of 1:1 association, and further comprising means for positioning an indicator to a first value before delivery of the therapy, and further comprising means for inhibiting the therapy delivering means from delivering a therapy in response to a determined post-therapy sinusal tachycardia and said indicator being positioned to said first value.

6. The device of claim 5 , wherein the classifying means further comprises means for determining whether the ventricular rate is out of the slow ventricular tachycardia range, and means for positioning said indicator to a second value before delivery of the therapy, and further comprising means for inhibiting the therapy delivering means from delivering a therapy in response to a determined post-therapy sinusal tachycardia and said indicator being positioned to said first value.

7. The device of claim 2 , wherein the classifying means further comprises:

means for comparing the ventricular rate to a predetermined frequency limit and determining whether the ventricular rate is higher than the predetermined frequency limit;

means for determining that the detected tachycardia corresponds to a ventricular fibrillation; and

wherein the analyzing means further comprises means for determining that the post-therapy detected tachycardia is a post-therapy sinusal tachycardia in response to the ventricular rate being lower than said predetermined frequency limit;

said device further comprising means for positioning an indicator to a first value before delivery of a therapy, and means for setting the indicator to a second value in response to the ventricular rate being higher than the predetermined frequency limit; and means for inhibiting the therapy delivering means from delivering a therapy in response to a determined post-therapy sinusal tachycardia and said indicator being positioned to said first value.

8. The device of claim 2 , wherein the classifying means further comprises;

means for determining a ventricular tachycardia in an absence of a 1:1 association;

means for comparing the ventricular rate to a predetermined frequency limit and determining whether the ventricular rate is higher than the predetermined frequency limit;

wherein the analyzing means further comprises means for determining that the post-therapy detected tachycardia is a post-therapy sinusal tachycardia in response to the ventricular rate being lower than said predetermined frequency limit;

said device further comprising;

means for positioning an indicator to a first value before delivery of the therapy and setting the indicator to a second value in response to the ventricular rate being higher than the predetermined frequency limit; and

means for inhibiting the therapy delivering means from delivering a therapy in response to a determined post-therapy sinusal tachycardia and said indicator being positioned to said first value.

9. The device of claim 1 wherein the classifying means further comprises means for determining that the detected tachycardia corresponds to a ventricular fibrillation and further comprising means for positioning an indicator to a first value before delivery of a therapy, and means for inhibiting the therapy delivering means in response to said indicator being positioned to said first value and a determined post-therapy sinusal tachycardia.

10. The device of the claim 9 , wherein the classifying means further comprises means for determining the ventricular rate is out of the slow ventricular tachycardia range, and means for positioning said indicator to a second value before delivery of the therapy, and means for inhibiting the shock therapy delivering means for delivering a therapy in response to a determined post-therapy sinusal tachycardia and said indicator being positioned to said first value.

11. The device of claim 1 further comprising means for memorizing an occurrence of a determined post-therapy sinusal tachycardia.

Assignments (2)
CHANGE OF NAME Recorded Jul 19, 2013
From: ELA MEDICAL S.A.S.
To: SORIN CRM SAS
Reel/Frame 030831/0859 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 21, 2003
From: HENRY, CHRISTINE; KROISS, DANIEL
To: ELA MEDICAL SA
Reel/Frame 013677/0097 →
Priority Claims (1)
FR 01 13135 · Oct 12, 2001 · national
Continuity (1)
Related Publication 20030097154A1 · May 22, 2003